Literature DB >> 22189200

Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease.

Laura Calabresi1, Sara Simonelli, Monica Gomaraschi, Guido Franceschini.   

Abstract

The lecithin:cholesterol acyltransferase (LCAT) enzyme is responsible for the synthesis of cholesteryl esters in human plasma and plays a critical role in high density lipoprotein (HDL) metabolism. Genetic LCAT deficiency is a rare metabolic disorder characterized by low HDL cholesterol levels. This paper reviews the genetic and biochemical features of LCAT deficiency, highlighting the absence of enhanced preclinical atherosclerosis in carriers, despite the remarkably low HDL cholesterol.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189200     DOI: 10.1016/j.atherosclerosis.2011.11.034

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  32 in total

1.  Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo.

Authors:  Lita A Freeman; Robert D Shamburek; Maureen L Sampson; Edward B Neufeld; Masaki Sato; Sotirios K Karathanasis; Alan T Remaley
Journal:  J Lipid Res       Date:  2019-02-26       Impact factor: 5.922

Review 2.  Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.

Authors:  Arshag D Mooradian; Michael J Haas
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 3.  HDL--is it too big to fail?

Authors:  Dominic S Ng; Norman C W Wong; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2013-01-15       Impact factor: 43.330

Review 4.  Novel concepts in HDL pharmacology.

Authors:  Alan T Remaley; Giuseppe D Norata; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2014-06-20       Impact factor: 10.787

Review 5.  Treating low high-density lipoprotein cholesterol: what is the evidence?

Authors:  Mirella P Hage; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-02       Impact factor: 3.565

6.  Reconstituted high-density lipoprotein therapies: a cause for optimism.

Authors:  Ali Javaheri; Daniel M Kolansky; Marina Cuchel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09       Impact factor: 8.311

Review 7.  Cholesterol and lipoprotein metabolism: Early Career Committee contribution.

Authors:  Hanrui Zhang; Ryan E Temel; Catherine Martel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09       Impact factor: 8.311

8.  Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement.

Authors:  Robert D Shamburek; Rebecca Bakker-Arkema; Bruce J Auerbach; Brian R Krause; Reynold Homan; Marcelo J Amar; Lita A Freeman; Alan T Remaley
Journal:  J Clin Lipidol       Date:  2015-12-23       Impact factor: 4.766

9.  Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study.

Authors:  Shigemasa Tani; Atsuhiko Takahashi; Ken Nagao; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2015-04-19       Impact factor: 2.037

Review 10.  Approach to the patient with extremely low HDL-cholesterol.

Authors:  Daniel J Rader; Emil M deGoma
Journal:  J Clin Endocrinol Metab       Date:  2012-10       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.